{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:45:33Z","timestamp":1780393533831,"version":"3.54.1"},"reference-count":45,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eskisehir Osmangazi University Research","award":["THD-2024-3230"],"award-info":[{"award-number":["THD-2024-3230"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by Neisseria meningitidis (Nm). While meningococcal vaccination is required for patients undergoing eculizumab therapy, there is limited knowledge about meningococcal carriage in children with aHUS. We aimed to evaluate (1) the prevalence of Nm carriage, (2) serogroup distribution, and (3) the immunization status of children undergoing eculizumab treatment for aHUS. Methods: The Meningo-aHUS study is a prospective, multi-center study evaluating meningococcal carriage in children and adolescents in T\u00fcrkiye receiving eculizumab for aHUS. We noted the age, gender, daycare, school, or university attendance, passive smoking status, previous infection and antibiotic use, and previous immunization history, including meningococcal vaccines, from the medical records of those children with aHUS. We collected nasopharyngeal samples, tested them for Nm using real-time polymerase chain reaction, and performed a serogroup analysis on the positive samples. Results: We collected nasopharyngeal samples from 62 children with aHUS. Out of 62 children, 61 (98.4%) had received at least one dose of the meningococcal vaccine. The median time since the last meningococcal vaccine dose was 15 months (1\u201359 months). We detected meningococcal carriage in three (4.8%, 95% CI 1.0\u201313.5) children, and all three strains were non-groupable (NG). No other serogroups were detected. Conclusions: Almost all the children received their risk-group meningococcal immunization, including booster doses. A 4.8% of children with aHUS carried NG meningococci and, no vaccine serogroups were detected. Patients treated with eculizumab remain profoundly susceptible to IMD due to these NG meningococcal strains. The occurrence of breakthrough cases and carriage of Nm, especially NG strains, highlights the significance of maintaining a state of constant alertness, promptly seeking medical attention, and swiftly treating any symptoms that align with IMD, regardless of their vaccination status or antibiotic prophylaxis.<\/jats:p>","DOI":"10.3390\/children11101164","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:16:37Z","timestamp":1727280997000},"page":"1164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Asli","family":"Kavaz Tufan","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ozak Batibay","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsah","family":"Kaya Aksoy","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Akdeniz University, 07070 Antalya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gulhan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Hacettepe University, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beltinge","family":"Demircioglu Kilic","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Erciyes University, 38280 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Buyukkaragoz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Gazi University, 06560 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Caltik Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-9714","authenticated-orcid":false,"given":"Hulya","family":"Nalcacioglu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Ondokuz Mayis University, 55139 Samsun, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulay","family":"Becerir","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Pamukkale University, 20160 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuran","family":"Cetin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Celegen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Kayseri Research and Training Hospital, 38050 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-6796","authenticated-orcid":false,"given":"Meltem","family":"Dinleyici","sequence":"additional","affiliation":[{"name":"Department of Social Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-536X","authenticated-orcid":false,"given":"Mucahit","family":"Kaya","sequence":"additional","affiliation":[{"name":"Diagen Biotechnology, 06070 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kilic","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-0134","authenticated-orcid":false,"given":"Ener Cagri","family":"Dinleyici","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future","volume":"25","author":"Gurevich","year":"2023","journal-title":"Paediatr. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.pcl.2022.07.006","article-title":"Hemolytic-Uremic Syndrome in Children","volume":"69","author":"Boyer","year":"2022","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","article-title":"Complement therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"56","author":"Wong","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules [II]: Agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Marantz","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","article-title":"Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease","volume":"80","author":"Crew","year":"2020","journal-title":"J. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/DHPS.S257009","article-title":"Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database","volume":"12","author":"Matsumura","year":"2020","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bozio, C.H., Isenhour, C., and McNamara, L.A. (2020). Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241989"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.1893-23","article-title":"Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study","volume":"63","author":"Okusa","year":"2024","journal-title":"Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_16","unstructured":"(2024, August 06). Vaccination Guideline for Patients under 18 Years of Age Treated with Eculizumab or Ravulizumab. Available online: https:\/\/www.atypicalhus.co.uk\/wp-content\/uploads\/2022\/12\/Vaccination-guideline-for-18-years-and-under-on-eculizumab-or-ravulizumab-FINAL-WEBSITE.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2018.03.087","article-title":"A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab","volume":"36","author":"Reher","year":"2018","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3201\/eid2408.180228","article-title":"Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab","volume":"24","author":"Konar","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","unstructured":"Immunization Recommendations for Children Primary Immune Deficiency (2024, September 06). National Social Pediatrics Society, Available online: https:\/\/www.sosyalpediatri.org.tr\/uploads\/Primer.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2023.08.052","article-title":"Antibodies against Neisseria meningitidis serogroups A, C, W and Y in serum and saliva of Norwegian adolescents","volume":"41","author":"Watle","year":"2023","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1080\/21645515.2016.1268304","article-title":"The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey","volume":"13","author":"Tekin","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yildiz, P., Sahin Tekin, M., Kaya, M., and Dinleyici, E.C. (2023). Nasopharyngeal Meningococcal Carriage among Older Adults in T\u00fcrkiye (MeninGOLD Study). Microorganisms, 11.","DOI":"10.3390\/microorganisms11082095"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"568.e1","DOI":"10.1016\/j.cmi.2016.03.022","article-title":"Comparative genomics of Neisseria meningitidis strains: New targets for molecular diagnostics","volume":"22","author":"Diene","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ladhani, S.N., Campbell, H., Lucidarme, J., Gray, S., Parikh, S., Willerton, L., Clark, S.A., Lekshmi, A., Walker, A., and Patel, S. (2019). Invasive meningococcal disease in patients with complement deficiencies: A case series (2008\u20132017). BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4146-5"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.3324\/haematol.2018.209692","article-title":"Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab","volume":"104","author":"Granoff","year":"2019","journal-title":"Haematologica"},{"key":"ref_29","first-page":"2802","article-title":"Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab","volume":"14","author":"Polat","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab Safety: Five-Year Experience from the Global Atypical Hemolytic Uremic Syndrome Registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.24953\/turkjped.2022.190","article-title":"Meningococcemia in a vaccinated child receiving eculizumab and review of the literature","volume":"65","author":"Kasap","year":"2023","journal-title":"Turk. J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/jpids\/piz071","article-title":"Meningococcal Serogroup B Disease in Vaccinated Children","volume":"9","author":"Abad","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-017-2951-8","article-title":"Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: Case report and review of management","volume":"96","author":"Friedl","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","article-title":"Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients","volume":"4","author":"Langereis","year":"2020","journal-title":"Blood Adv."},{"key":"ref_39","first-page":"298","article-title":"Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab","volume":"35","author":"Rohn","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1586\/erv.12.29","article-title":"The dynamic and changing epidemiology of meningococcal disease at the country-based level: The experience in Turkey","volume":"11","author":"Dinleyici","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00060-20","DOI":"10.1128\/mSphere.00060-20","article-title":"Multicenter Hospital-Based Prospective Surveillance Study of Bacterial Agents Causing Meningitis and Seroprevalence of Different Serogroups of Neisseria meningitidis, Haemophilus influenzae Type b, and Streptococcus pneumoniae during 2015 to 2018 in Turkey","volume":"5","author":"Ceyhan","year":"2020","journal-title":"mSphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinf.2023.10.011","article-title":"Meningococcal disease in the Middle East: A report from the Global Meningococcal Initiative","volume":"88","author":"Abuhasan","year":"2024","journal-title":"J. Infect."},{"key":"ref_43","unstructured":"Kizil, M.C., Kara, Y., Kaya, M., Karbuz, A., Oz, F.N., Ciftci, E., Kurugol, Z., \u0130seri Nepesov, M., Celebi, S., and Cetin, B.S. (2024, August 05). The Prevalence, Serogroup Distribution and Risk Factors of Meningococcal Carriage in Children, Adolescents and Young Adults in Turkiye. 42 Annual Meeting of European Society for Pediatric Infectious Disease Abstract Book. Available online: https:\/\/info.kenes.com\/Flip\/ESPID24_ESPID24\/?_ga=2.177669356.852219706.1722942376-453645702.1716531319."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2251825","DOI":"10.1080\/21645515.2023.2251825","article-title":"Real-world impact and effectiveness of MenACWY-TT","volume":"19","author":"Villena","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmi.2017.07.011","article-title":"Post-eculizumab meningococcaemia in vaccinated patients","volume":"24","author":"Lebel","year":"2018","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/10\/1164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:33Z","timestamp":1760112153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/10\/1164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["children11101164"],"URL":"https:\/\/doi.org\/10.3390\/children11101164","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}